Back to Learn Skin with Dr. Raja and Dr. Hadar

Podcast Episode

Episode 237: Psoriasis Insights – Bridging Science and Clinical Practice

Learn Skin with Dr. Raja and Dr. Hadar··30 August 2026·34 min

About this episode

Want to hear the latest on psoriasis research? We've got just the expert. This week, we're joined by Dr. Wilson Liao as he as he explores emerging science, clinical challenges, and integrative care strategies to bridge the gap between research and practice in psoriasis management. Dr. Wilson Liao is Professor of Dermatology and Director of the Psoriasis Center at the University of California San Francisco. Dr. Liao is a dermatologist with expertise in biologic therapy and phototherapy and human geneticist who has contributed to the identification of over 60 psoriasis susceptibility genes. He has led numerous genetic, transcriptomic, proteomic, and microbiome studies in psoriasis. Dr. Liao's group has also investigated the impact of environmental factors on psoriasis, including diet, stress, exercise, sleep, and pollution. He currently serves as a member of the National Psoriasis Foundation Medical Board and Scientific Advisory Committee. Learning Objectives: a) Summarize key advances in psoriasis immunopathogenesis and targeted therapies. b) Apply evidence-based approaches to integrating emerging treatments and integrative care in clinical practice. c) Identify strategies for comorbidity management and patient-centered communication Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. To learn more about Psoriasis, visit LearnSkin.com to enroll in the Advancing Clinician Competence in Psoriasis and Psoriatic Arthritis Management: Emerging Immune Pathways and Integrative Care. In collaboration with the National Psoriasis Foundation and supported by independent educational grants from AbbVie, Johnson & Johnson, Ortho Dermatologics, Sun Pharmaceutical Industries, Inc, Takeda Pharmaceuticals U.S.A., Inc and UCB